EU health stakeholders set up EMVO to help fight counterfeit medicines

Major European health care stakeholders have taken a major step to secure the legitimate pharmaceutical supply chain against the risk of falsified medicines, as required by the European Union Falsified Medicines Directive.

EFPIA, the European Federation of Pharmaceutical Industries and Associations, the EGA, the European Generic and Biosimilar medicines Association, PGEU, the Pharmaceutical Group of the European Union, GIRP, the European Association of Pharmaceutical Full-line Wholesalers and EAEPC, the European Association of Euro-Pharmaceutical Companies, have [today] announced the establishment of the European Medicines Verification Organization (EMVO).

EMVO, a not-for-profit stakeholder organization incorporated in Luxembourg, represents a key tool to combat the emergence of falsified medicines in the EU legitimate supply chain and improve patient safety. It represents the culmination of four years of intensive work towards a dependable and secure pharmaceutical verification system. Financed in the initial stages by the pharmaceutical industry, EMVO will now assume responsibility for the European Hub, which links national verification systems throughout Europe, a design agreed by the European Stakeholders.